scholarly journals Male breast cancer diagnosis stages, treatment and survival in Uruguay: a retrospective analysis of a case series

2021 ◽  
pp. BMT56
Author(s):  
Natalia Camejo ◽  
Cecilia Castillo ◽  
Andrea Schiavone ◽  
Ana L Alfonso ◽  
Dahiana Amarillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Histological Grade ◽  
Case Series ◽  
Postmenopausal Breast Cancer ◽  
Rare Condition ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Breast Cancers ◽  
Chemotherapy Adjuvant

Male breast cancer (MBC) is a rare condition which, while sharing some similarities with breast cancer in women, has a unique disease profile of its own. Aim: To understand the characteristics of MBC and its management in Uruguay. Patients & methods: Retrospective observational study that included patients diagnosed with MBC. Results: 22 cases of MBC were found. The median age at diagnosis was 62.5 years. Symptoms included self-detected lump in 17 patients (77.3%) and nipple retraction in seven (22.7%). Ductal carcinomas of histological grade 2–3 were found in 20 patients (90.9%) and stage I–II disease was most commonly encountered (15 patients, 68.1%). Neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy and tamoxifen were offered to 16 (73%), 12 (54.5%), 17 (65.4%) and 20 (90.9%) patients, respectively. Conclusion: MBC behaves and is treated in many aspects like postmenopausal breast cancer. Further multi-institutional, prospective studies are needed for better understanding and management of male breast cancers.

Male Breast Cancer: Current Essentials & Review

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Kadam SS ◽  
◽  
Kadam T ◽  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Case Series ◽  
Rare Condition ◽  
Female Breast Cancer ◽  
The Body ◽  
Male Breast ◽  
Breast Cancers ◽  
Elderly Males ◽  
Risk Of Cancer

Background: Breast cancer in male is a very rare condition but some of the reported case series had shown that its incidence is increasing over the last 25 years. The etiology of breast cancer in males differs from that of females in many ways. The literature lacks the prospective randomized evidences supporting the treatment of male breast cancer. Only retrospective evidences are available and all guidelines are extrapolated from the best available data of treatment of female breast cancer. Therefore, we have reviewed, compiled and tried to present the best available literature which highlights the treatment of male breast cancer .The reported incidence of breast cancer in men is around 1.2%-2% of all cancers in males and less than 1% of all breast cancers in both sexes. If it involves both breasts then it becomes an extremely uncommon condition which accounts for only 1% of all male breast cancer. Elderly males are most commonly diagnosed with breast cancer and they are approximately 5 to 10 years older than the women. The most common reason of breast cancer in males is excess of estrogen in the body and all conditions which leads to hyperestrogenism are responsible for increasing the risk of cancer.

Inmunophenotypic profiles of male breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21180-21180
Author(s):  
T. Martin Gomez ◽  
B. Torio ◽  
I. Ruiz ◽  
F. Arranz ◽  
A. Arizcun
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
In Situ Hybridisation ◽  
Case Series ◽  
Response To Therapy ◽  
Male Breast ◽  
Breast Cancers ◽  
Luminal A ◽  
Luminal B ◽  
Female Breast

21180 Background: Recently, inmunophenotypic characterization methods have allowed identification of female breast carcinomas into separate groups showing different behaviour and response to therapy: luminal A phenotype (RE +, HER2-neu - ), luminal B (RE +, HER2- neu + ), basal like (RE -, HER2-neu - ). In this study, we used immunohistochemistry to investigate the inmunophenotypic profile distribution of male breast cancer. Methods: all the male breast cancers were obtained from the files of the Departments of Pathology of Hospital Río Carrión in Palencia, Spain, since 1996. A total of 9 cases were reviewed to confirm the diagnosis and to characterize each tumour. The following CK immunohistochemistry was performed: 8/18 and 5 (Dako, Carpinteria, CA, USA) in a Dako autostainer. ER was interpreted as positive if > 10% of the cells were staining. Normal skin and tonsils were used as positive controls for the CK and a known breast cancer for the ER immunohistochemistry. Results: five cases expressed RE and were HER2-neu negative, so they have a luminal-A phenotype. The four cases that expressed the luminal-B pehnotype expressed RE and HER2-neu; we demonstrated gene amplification of the HER-neu gene using fluorescent in situ hybridisation (FISH) in those cases. Respect the CKs profile, all cases were positive for CK 8/18 and negative with CK 5, vimentin and p63, characteristic of luminal-like CK expression profile, according wiht the literature. Conclusions: this is the first case series of male breast cancer patients that provides inmunophenotypic profile data on this rare disease in only one center in Spain. We comunicate that the vast majority of these tumours express the phenotype of luminal-like CKs. None of our patients were basal-like tumours. The percentage expression of Her-2 parallels the finding in female breast cancers and this should be analysed for its predictive significance, according to new specific biological treatments. No significant financial relationships to disclose.

scholarly journals Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients

Diagnostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 269
Author(s):  
Gianluca Tedaldi ◽  
Michela Tebaldi ◽  
Valentina Zampiga ◽  
Ilaria Cangini ◽  
Francesca Pirini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Case Series ◽  
Brca2 Gene ◽  
Brca1 Gene ◽  
Cancer Predisposition ◽  
Male Breast ◽  
Breast Cancers ◽  
Brca1 And Brca2 ◽  
Pathogenic Variants

Male breast cancer (MBC) is a rare tumor, accounting for less than 1% of all breast cancers. In MBC, genetic predisposition plays an important role; however, only a few studies have investigated in depth the role of genes other than BRCA1 and BRCA2. We performed a Next-Generation Sequencing (NGS) analysis with a panel of 94 cancer predisposition genes on germline DNA from an Italian case series of 70 patients with MBC. Moreover, we searched for large deletions/duplications of BRCA1/2 genes through the Multiplex Ligation-dependent Probe Amplification (MLPA) technique. Through the combination of NGS and MLPA, we identified three pathogenic variants in the BRCA1 gene and six in the BRCA2 gene. Besides these alterations, we found six additional pathogenic/likely-pathogenic variants in PALB2, CHEK2, ATM, RAD51C, BAP1 and EGFR genes. From our study, BRCA1 and BRCA2 emerge as the main genes associated with MBC risk, but also other genes seem to be associated with the disease. Indeed, some of these genes have already been implicated in female breast cancer predisposition, but others are known to be involved in other types of cancer. Consequently, our results suggest that novel genes could be involved in MBC susceptibility, shedding new light on their role in cancer development.

scholarly journals Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jane Bayani ◽  
Coralie Poncet ◽  
Cheryl Crozier ◽  
Anouk Neven ◽  
Tammy Piper ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Univariate Analysis ◽  
Gene Signature ◽  
Male Breast ◽  
Risk Scores ◽  
Breast Cancers ◽  
Academic Risk ◽  
Genomic Grade Index ◽  
Prognostic Utility

AbstractMale breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.

Male Versus Female Breast Cancers

2003 ◽  
Vol 127 (1) ◽  
pp. 36-41 ◽  
Author(s):  
D. Muir ◽  
R. Kanthan ◽  
S. C. Kanthan
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Male Breast Cancer ◽  
Male Breast ◽  
High Grade ◽  
Breast Cancers ◽  
Receptor Status ◽  
Female Breast ◽  
Grade 3

Abstract Context.—The rate of male breast cancer is a small fraction of that observed in females, thus severely limiting our understanding of the pathogenesis of this condition. It remains unclear whether the biological behavior and tumor progression associated with male breast cancer parallel that of the female form. Objectives.—To evaluate the immunohistochemical profile of male breast carcinomas and to compare this profile with that of stage-matched female breast cancers. Design.—Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Foundation over a period of 26 years (1970–1996). Fifty-nine of these cases had formalin-fixed, paraffin-embedded tissue blocks available for the purposes of this study. All cases were reviewed and a standardized modified Bloom-Richardson grading criterion was applied. Estrogen receptor status, progesterone receptor status, c-Erb-B2 expression, p53 expression, and Bcl-2 expression were evaluated by immunohistochemistry. Results from 240 consecutive cases of stage-matched female breast cancers analyzed in the same laboratory were used as a standard set for comparison. Results.—Male breast cancers tended to be high grade (85% grade 3) in comparison with the female breast cancers (50% grade 3). In descriptive analysis across all stages of disease, male carcinomas were more frequently estrogen receptor positive (81% vs 69%) than their female counterparts. Despite their high grade, they were less likely to overexpress p53 (9% vs 28%) and Erb-B2 (5% vs 17%) than the female counterparts. There was no significant difference in either progesterone receptor (63% vs 56%) or Bcl-2 (79% vs 76%) overexpression. Stratified analysis by stage-matched controls showed no statistically significant differences among the men and women with stage I disease. However, in stage II–matched samples, statistically significant differences were observed between the 2 groups. The male cancers were more likely to overexpress estrogen receptor (81.6% vs 64.4%, P = .04), progesterone receptor (71.1% vs 47.5%, P = .01), and Bcl-2 (78.9% vs 69.4%, P = .20). They also showed statistically significant lower expression of p53 (7.9% vs 36.3%, P = .001) and Erb-B2 (5.3% vs 23.8% P = .01). Conclusion.—Male breast cancers display distinct immunophenotypic differences from those occurring in women, implying a different pathogenesis in the evolution and progression of this disease. Such differences may play key roles in therapeutic management, warranting different treatment strategies in comparison to female breast cancers.

scholarly journals Male Breast Cancer- Report of Two Cases

1970 ◽  
Vol 21 (1) ◽  
pp. 80-82
Author(s):  
M Dayem Uddin ◽  
ABM Abdul Hannan
Keyword(s):  
Breast Cancer ◽  
Clinical Manifestation ◽  
Male Breast Cancer ◽  
Signs And Symptoms ◽  
Male Breast ◽  
Breast Cancers ◽  
Early Signs ◽  
Bangladeshi Population

Male breast cancer is rare. It accounts for 0.2% of all cancers, and 1% all breast cancers. Most patients present late for several reasons, including the absence of early signs and symptoms, and reduced awareness of the existence of such pathology among patients and physicians, Reporting these cases from among the Bangladeshi population, we tried to observe any differences in clinical manifestation from those reported in the literature, and aimed to increase the value assigned to male breast as a source of pathology among patients and physicians as well.   doi: 10.3329/taj.v21i1.3226 TAJ 2008; 21(1): 80-82

scholarly journals A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer

2019 ◽  
Vol 7 ◽  
pp. 232470961984723
Author(s):  
Leila Moosavi ◽  
Phyllis Kim ◽  
An Uche ◽  
Everardo Cobos
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Male Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Breast Mass ◽  
Medical Attention ◽  
Cancer History ◽  
History Of ◽  
The Right

In this article, we present a patient diagnosed synchronously with metastatic male breast cancer and prostate cancer. This is a 63-year-old male and recent immigrant from Nigeria, who sought medical attention for progressively worsening of shortness of breath and acute progression of a chronic right breast mass. An invasive breast carcinoma was diagnosed by the core biopsy of the right breast mass. Within 2 months of his breast cancer diagnosis, the patient also was diagnosed with prostate adenocarcinoma after being worked up for urinary retention. By presenting this patient with a synchronous diagnosis with metastatic male breast cancer and prostate cancer, history of chronic right breast mass, and gynecomastia, we speculate on possible cancer etiologies and risk factors.

scholarly journals Management and Outcomes of Male Breast Cancer in Zaria, Nigeria

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Adamu Ahmed ◽  
Yahaya Ukwenya ◽  
Adamu Abdullahi ◽  
Iliyasu Muhammad
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Advanced Disease ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Tumor Diameter ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Modified Radical Mastectomy ◽  
Male Patients

Male breast cancer is an uncommon disease accounting for only 1% of all breast cancers. We present the evaluation, treatment and outcome of male patients seen with breast cancer in our institution. Male patients that had histological diagnosis of breast cancer from 2001 to 2010 were retrospectively evaluated. After evaluation patients were treated with modified radical mastectomy. Combination chemotherapy was given to patients with positive axillary lymph nodes. Radiotherapy and hormonal therapy were also employed. There were 57 male patients with breast cancer which accounted for 9% of all breast cancers seen during the study period. Their mean age was 59 ± 2.3 years. The mean tumor diameter was 13 ± 2.5 cm. Fifty three (93%) patients presented with advanced disease including 15 with distant metastasis. Four patients with stage II disease were treated with modified radical mastectomy, chemotherapy and tamoxifen. Of the 30 patients with sage III disease that had modified radical mastectomy, complete axillary clearance and tumor free margins were achieved in 25. Overall 21 (36.8%) patients were tumor free at one year. Overall 5-year survival was 22.8%. In conclusion, male patients with breast cancer present with advanced disease which is associated with poor outcome of treatment.

Male breast cancer: Molecular pathology and demographics of a case series

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9723-9723
Author(s):  
S. Pant ◽  
S. Venkatappa ◽  
S. Sethi ◽  
S. Lightfoot ◽  
A. Tfayli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Molecular Pathology ◽  
Case Series ◽  
Male Breast
Sign in / Sign up

Export Citation Format

Share Document